CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
Last trade$26.64
Day change+$0.22 (+0.83%)
Day range$26.37 – $29.19
Volume147,396
Market cap$1.03B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.03B
Price / earnings
—
Price / book
8.73×
Price / sales
9.44×
EV / sales
9.24×
EV / EBITDA
-13.41×
Profitability
Earnings per share
-$1.90
Return on assets
-47.25%
Return on equity
-62.86%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.17×
Current ratio
8.18×
Quick ratio
7.79×
Cash ratio
2.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.19M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CBLL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$29.34M
$28.1M
$26.49M
$24.78M
$22.59M
$21.2M
$20.49M
$18.53M
Cost of revenue
$3M
$2.16M
$3.37M
$3.14M
$2.65M
$2.52M
$2.48M
$2.3M
Gross profit
$26.34M
$25.94M
$23.12M
$21.64M
$19.94M
$18.68M
$18.01M
$16.24M
Selling, general and administrative
$39.49M
$39.17M
$37.71M
$31.18M
$29.61M
$28.78M
$27.97M
$25.21M
Research and development
$7.4M
$6.75M
$6.16M
$5.06M
$4.98M
$4.85M
$4.25M
$3.91M
Total operating expenses
$46.89M
$45.92M
$43.87M
$36.24M
$34.59M
$33.63M
$32.21M
$29.12M
Operating income
-$20.55M
-$19.98M
-$20.75M
-$14.6M
-$14.65M
-$14.95M
-$14.21M
-$12.88M
Interest expense
-$267K
-$438K
-$434K
-$462K
-$480K
-$477K
-$471K
-$499K
Income before taxes
-$21.35M
-$19.27M
-$19.74M
-$13.53M
-$13.47M
-$13.64M
-$12.78M
-$12.58M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$21.35M
-$19.27M
-$19.74M
-$13.53M
-$13.47M
-$13.64M
-$12.78M
-$12.58M
Net income attributable to common shareholders
-$21.35M
-$19.27M
-$19.74M
-$13.53M
-$13.47M
-$13.64M
-$12.78M
-$12.58M
EBITDA
-$20.3M
-$19.74M
-$20.51M
-$14.31M
-$14.26M
-$14.63M
-$13.87M
-$12.52M
Basic earnings per share
-$0.55
-$0.51
-$0.52
-$0.36
-$0.37
-$0.38
-$0.36
-$0.40
Diluted earnings per share
-$0.55
-$0.51
-$0.52
-$0.36
-$0.37
-$0.38
-$0.36
-$0.40
Recent news
Company coverage with links to the original publishers.
CeriBell, Inc. (CBLL) reported a quarterly loss of $0.48 per share, beating consensus estimates of $0.50 loss, with revenues of $29.34 million exceeding expectations by 0.70%. However, losses widened year-over-year from $0.37 to $0.48 per share. The stock has gained 22.9% year-to-date but carries a Zacks Rank #3 (Hold) rating, with the Medical-Products industry ranking in the bottom 35% of sectors.
CeriBell, Inc. reported Q3 2026 revenue of $29.34 million, beating estimates by 0.7% with 29.9% year-over-year growth. The company posted an EPS of -$0.48, outperforming the consensus estimate of -$0.50 by 4%. Key metrics showed Total Active Accounts at $747 million and strong growth in EEG headband revenue at $22.24 million (+30.6% YoY). The stock holds a Zacks Rank #3 (Hold) rating and has returned 8.5% over the past month.
Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.
Ceribell obtained FDA 510(k) clearance for its ClarityⓇ algorithm, becoming the first AI-powered point-of-care EEG technology capable of detecting electrographic seizures across all patient ages, from pre-term neonates to adults.
Medical technology company Ceribell announced the appointment of Erica Rogers to its Board of Directors, bringing over three decades of healthcare leadership experience to help expand nationwide access to their point-of-care EEG system.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.